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1 Clinical Pharmacology, Medical University of Vienna, Vienna; 2 Immunbiologische Forschung GmbH, Polymun Scientific, Klagenfurt, Austria; and 3 Inc., SignPath Pharma, Quakertown, United States Introduction: Curcumin possesses anticancer, anti-inflammatory, antioxidant, and antimicrobial properties. Curcumin has a poor oral bioavailability and solubility in plasma. Accordingly, various drug delivery systems, such as liposomal preparation, have been developed for intravenous administration. However, animal studies have shown dose-dependent hemolysis after infusion of liposomal curcumin. Because blood cells are the first point of contact for liposomal curcumin when administered intravenously, we investigated the influence of curcumin on human red blood cell (RBC) morphology in vitro. Patients (or Materials) and Methods: Whole blood buffered with EDTA was incubated with different concentrations (1, 10, 100 μ g/ mL) of free or liposomal formulations of curcumin. RBC morphology and mean cellular volume were examined after 30 minutes, 1 hour, 2 hours, and 4 hours of incubation. Results: Dose-dependent echinocyte formation was observed after incubation with free and liposomal Curcumin, with a threshold concentration of 10 µg/mL and peak effect after 30 minutes of incubation. Treatment with empty liposomes also resulted in RBC shape change. A concomitant increase in mean red blood cell volume was detectable. Conclusion: Curcumin, liposomes and liposomal curcumin dosedependently change RBC morphology. This effect is additive and may represent a first sign of toxicity following intravenous administration. Biochemical Estimations in Colonic Tissues: Malondialdehyde (MDA) Assay, reduced glutathione (GSH) Assay, Cyclooygenase-2 (COX-2) activity measurement, tumor necrosis factor-α (TNF-α 1 Determination, platelet activating factor (PAF) activity measurement, transformaing growth factor-β (TGF-β ) determination: Results: Treatment by curcumin succeeded to significantly decrease the percent of ACF and tended to normalize back the histologic changes retrieved in adenomatous and stromal cells induced by DMH. The drug also significantly elevated GSH and significantly reduced most of the accompanying biochemical elevations (namely MDA, TNF-α , TGF-β , and COX2) observed in colonic carcinomatous tissue, induced by DMH, thus succeeding to revert that of MDA, COX2& TGF-β back to near normal as justified by being nonsignificantly altered compared with normal controls. The only exception was PAF, which was insignificantly altered by the drug. Conclusion: When taken together, it could be concluded that curcumin possess the potentiality to halt some of the orchestrated crosstalk between cancerous transformation and its microenvironmental niche that contributes to cancer initiation, progression, and metastasis in this experimental cancer colon model. Envisioning these merits to a drug with an already known safety preferentiality, awaits final results of current ongoing clinical trials, before curcumin can be added to the new therapeutic armamentarium of anticancer therapy. Disclosure of Interest: None declared. (Bu) . In vitro elucidation of involvement of CYPs in the oxidation of Bu metabolites is cumbersome due to the volatile nature of tetrahydrothiophene and nonavailability of sensitive quantitation methods. This study is aimed at exploring the association of CYP2C9, CYP2C19, CYP2B6, FMO genotypes, and sulfolane (Su) levels in children undergoing hematopoietic stem cell transplantation (HSCT).The relation of genotypes with the outcomes of HSCT was also explored. Patients (or Materials) and Methods: Sixty-six children receiving IV Bu-based myeloablative conditioning regimen were genotyped for common functional variant alleles in CYP2C9 (*2 and *3), CYP2C19 (*2 and *17), FMO3 (rs2266780, rs2266782 and rs1736557) and CYP2B6 (*5 and *9). Plasma levels of Bu and its metabolite Su were measured after dose 9 from a subset of 44 patients for whom plasma samples after dose 9 were available. The ratio of Bu to Su was taken as a metabolic ratio (MR) to compare among genotype groups. The MRs (Bu/Su), Bu and Su levels between different genotype groups were compared using nonparametric tests. The distribution of age, and gender between the groups was compared using t test and chisquare test, respectively. Cumulative incidence of overall survival and event-free survival were estimated using Kaplan-Meier curves and log-rank test was used to compare the difference between genotype groups or groups divided on the basis of MR, in a univariate analysis. Multivariate analysis was performed using cox-regression analysis. Introduction: Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) widely used in antiretroviral therapy (ART) in sub-Saharan Africa. Approximately 5% of patients receiving NVP-containing regimens develop hypersensitivity reactions (HSRs). These can manifest as more severe reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and hepatotoxicity. Various human leukocyte antigen (HLA) alleles have been associated to NVP-induced HSRs in populations of differing ethnicity. Carriage of HLA-C*04:01 is associated with an increased risk of SJS in our Malawian cohort. We investigated whether expression levels of miR-148a, a microRNA known to regulate HLA-C expression, differ in serum samples from hypersensitive and tolerant patients. The aim of the study was to identify the role of posttranscriptional regulation of HLA-C expression in HLAassociated NVP-induced HSRs. Patients (or Materials) and Methods: A total of 1117 HIV-positive patients in Malawi treated with a NVP-containing regimen were recruited prospectively. Of these, 57 patients developed NVP-induced HSRs. MicroRNA expression was analyzed using TaqMan probebased qPCR in available serum samples of 41 tolerant and 33 hypersensitive patients. Expression levels were compared in hypersensitive patients at baseline (n = 19) and during the acute phase of the reaction (n = 26). Tolerant baseline (n = 25) and week 6 (n = 27) samples were used as controls. Data were analyzed using nonparametric tests. Results: There was no significant difference in the baseline expression of miR-148a between tolerant and hypersensitive patients. In our cohort, miR-148a expression showed a 4.6-fold increase in acute hypersensitive samples, when compared with baseline hypersensitive (P = 0.008). This was not observed in samples from tolerant patients. Conclusion: Our study has identified an increase in miR-148a expression levels in serum samples from Malawian nevirapine hypersensitive patients during the acute phase. The reason(s) for the change in expression during the acute phase are unclear but may be related to the ongoing inflammation associated with a HSR. Further investigation is required to elucidate the mechanism of the rise in microRNA levels and any implications this may have on the severity and duration of the HSR. Disclosure of Interest: None declared. Resistance to anticonvulsants affects one third of all epilepsy patients. Limited bioavailability of the drug at the target site caused by increased expression of efflux transporters on the blood brain barrier or alterations of target genes as well as seizure-induced neural reorganization are potential mechanisms for therapy resistance. There is increasing evidence that expression of microRNAs (miRNAs) is deregulated in neuronal disorders. We hypothesize that an altered miRNA regulation of target genes is involved in drug resistance in epilepsy. Patients (or Materials) and Methods: Hippocampal focal and cortical nonfocal brain tissue samples from 13 patients diagnosed with MTS (mesial temporal sclerosis) who underwent neurosurgery have been screened for miRNA expression using TaqMan® low-density arrays. To compare miRNA expression between brain regions, a Mann-Whitney U test was performed using R (Bioconductor). In silico approaches for both a hypothesis-based (efflux-transporter and target gene) as well as a hypothesis-free approach were used
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